CA2466931A1 - Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques - Google Patents

Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques Download PDF

Info

Publication number
CA2466931A1
CA2466931A1 CA002466931A CA2466931A CA2466931A1 CA 2466931 A1 CA2466931 A1 CA 2466931A1 CA 002466931 A CA002466931 A CA 002466931A CA 2466931 A CA2466931 A CA 2466931A CA 2466931 A1 CA2466931 A1 CA 2466931A1
Authority
CA
Canada
Prior art keywords
interferon
ifn
administration
administered
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002466931A
Other languages
English (en)
Inventor
Lorianne K. Masuoka
Min F. Kwan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2466931A1 publication Critical patent/CA2466931A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode permettant de prévenir ou d'atténuer les symptômes de la sclérose en plaques par l'administration au système nerveux central d'un interféron et d'un anticorps anti-CD40. Les interférons comprennent l'interféron-.beta. et ses mutéines, telles que l'IFN-.beta.¿ser17?.
CA002466931A 2001-11-26 2002-11-26 Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques Abandoned CA2466931A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33335501P 2001-11-26 2001-11-26
US60/333,355 2001-11-26
PCT/US2002/038164 WO2003045978A2 (fr) 2001-11-26 2002-11-26 Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques

Publications (1)

Publication Number Publication Date
CA2466931A1 true CA2466931A1 (fr) 2003-06-05

Family

ID=23302439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002466931A Abandoned CA2466931A1 (fr) 2001-11-26 2002-11-26 Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques

Country Status (5)

Country Link
EP (1) EP1455812A4 (fr)
JP (1) JP2005510570A (fr)
AU (1) AU2002346581A1 (fr)
CA (1) CA2466931A1 (fr)
WO (1) WO2003045978A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044854A2 (fr) * 2003-11-04 2005-05-19 Chiron Corporation Anticorps monoclonaux anti-cd40 antagonistes et procedes d'utilisation associes
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2007053767A1 (fr) 2005-11-01 2007-05-10 Novartis Ag Utilisations d'anticorps anti-cd40
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CN102585011A (zh) * 2012-02-10 2012-07-18 中国农业大学 一种犬α干扰素衍生物的制备方法与应用
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
JP2021169423A (ja) * 2020-04-15 2021-10-28 洋悦 松川 製剤投与方法
EP4172323A1 (fr) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Virus modifiés pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same

Also Published As

Publication number Publication date
JP2005510570A (ja) 2005-04-21
AU2002346581A8 (en) 2003-06-10
EP1455812A4 (fr) 2006-03-22
WO2003045978A2 (fr) 2003-06-05
WO2003045978A3 (fr) 2003-07-31
AU2002346581A1 (en) 2003-06-10
EP1455812A2 (fr) 2004-09-15

Similar Documents

Publication Publication Date Title
US6991785B2 (en) Method for administering a cytokine to the central nervous system and the lymphatic system
CA2466931A1 (fr) Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques
US20120087934A1 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
EP1740200B1 (fr) Il-6 pour traitement ou prevention d'une neuropathie induite par une chimiotherapie
AU2005221682A1 (en) Pharmaceutical compositions comprising interferon-tau
Jacobs et al. Treatment of multiple sclerosis with interferons
US8178083B2 (en) Treatment of optic neuritis
EP1602378A1 (fr) Méthode d'administration d'une cytokine au système nerveux central et au systéme lymphatique
US20030027760A1 (en) Composition and methods to improve neural outcome
WO1999016460A2 (fr) Complexes d'apolipoproteine e/facteur de croissance et procedes d'utilisation
CA2579166A1 (fr) Utilisation du il-17f dans le traitement et/ou la prevention de maladies neurologiques
JP4490104B2 (ja) 脱髄性疾患における腫瘍壊死因子とインターフェロンの組み合わせ
BA32 TGF-B (pglml)
EP1179020A1 (fr) Recuperation de cellules photoreceptrices induite par il-1beta administree a faible dose et ne provoquant pas de dysplasie retinienne

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead